Key result
Recent studies suggest TTN truncation variants in dilated cardiomyopathy act via a dominant-negative poison peptide mechanism by integrating into the sarcomere, alongside haploinsufficiency.
Highlights new pathophysiological insights into how TTN truncation variants cause dilated cardiomyopathy through both dominant-negative integration and reduced full-length protein levels.
Titin (TTN) is one of the largest and most complex proteins expressed in humans, and truncation variants are the most prevalent genetic lesion identified in individuals with dilated cardiomyopathy (DCM) or other disorders of impaired cardiac contractility. Two reports in this issue of the JCI shed light on a potential mechanism involving truncated TTN sarcomere integration and the potential for disruption of sarcomere structural integrity. Kellermayer, Tordai, and colleagues confirmed the presence of truncated TTN protein in human DCM samples. McAfee and authors developed a patient-specific TTN antibody to study truncated TTN subcellular localization and to explore its functional consequences. A "poison peptide" mechanism emerges that inspires alternative therapeutic approaches while opening new lines for inquiry, such as the role of haploinsufficiency of full-length TTN protein, mechanisms explaining sarcomere dysfunction, and explanations for variable penetrance.
No takes yet. Share an insight, caveat, or question.
Hinson et al. (2024) conducted an editorial in Dilated Cardiomyopathy (DCM). TTN truncation variants was evaluated. Recent studies suggest TTN truncation variants in dilated cardiomyopathy act via a dominant-negative poison peptide mechanism by integrating into the sarcomere, alongside haploinsufficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: